Heron Therapeutics Inc
HRTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$76.87M
Close$
$3.67
874.6% upside
Current Fair Value
874.6% upsideUndervalued by 874.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $76.87 Million |
|---|---|
| Enterprise Value | $204.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 1.63 |
| Outstanding Shares | 190,335,000 |
Return
| Return on Equity | -492.89% |
|---|---|
| Return on Assets | -13.50% |
| Return on Invested Capital | -10.18% |
Valuation & Multiples
| P/E Ratio | -2.17 |
|---|---|
| PEG | -1.66 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.35 |
| Enterprise Value to EBIT | -12.55 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.73 |
| Debt to Equity | 21.48 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$42.19 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$37.50 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.8726▼ 2.61% |
|---|---|
| Total Calls | 1,138,400▲ 1.26% |
| Total Puts | 2,131,800▼ 0.13% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 71.05%▼ 11.67% |
|---|---|
| Total Invested | $57.92M▼ 53.90% |
| Investors Holding | 170▼ 3.00% |
ESG Score
No data
About Heron Therapeutics Inc
128 employees
CEO: Barry Quart Heron Therapeutics, Inc. is a biotechnology firm dedicated to developing innovative therapeutic solutions for significant unmet patient needs. At the heart of its pipeline is the proprietary Biochronomer drug delivery system. This techno...